THE ARISING · Markets & Strategy
Tiny Health Raises $33 Million Series B as Adult Microbiome Testing Overtakes Pediatric
A company that began by testing babies' guts now sells more tests to adults. Tiny Health, based in Austin, has raised a $33 million Series B, according to Longevity.Technology.
BCapital Group led the round. Total funding now stands at $46 million. Other investors include Spero Ventures, The Venture City, Overwater Ventures and new backers, according to the source.
The shift in customer mix is the strategic point. Adult testing volumes now exceed pediatric volumes, according to the report. Longevity.Technology reports that nearly 200,000 customers and more than 6,000 healthcare practitioners use the platform.
The company has added longevity-focused products, including Gut Microbiome Age and Gut Resilience scores, according to Longevity.Technology. The source does not say how these scores are calculated or validated, and the notes do not address regulatory treatment.
Its business-to-business arm, called Powered by Tiny, grew fourfold last year, according to the source. That suggests practitioners and partners are a growing sales channel alongside direct consumers. The notes give no revenue figures, so the scale of that growth is unclear.
CEO Cheryl Sew Hoy said, according to the source: "no one else was building for the whole lifespan." That is the company's own account of its positioning. The notes do not assess competitors.
What to watch next
Whether Tiny Health discloses revenue or evidence supporting its new longevity scores as it deploys the new capital.